People move between these drugs constantly, and for good reasons: an insurer reshuffles its preferred list, side effects prove intolerable, progress stalls, or someone reaches the top of a ladder with weight still to lose.
No label covers a move from one GLP-1 drug to another. (Wegovy's label covers only switching between its own injection and tablet.) The manufacturers tested their drugs against placebo, not against each other's discontinuation. This card combines the titration rules with what endocrinologists do in practice. Use it to talk a switch through with your prescriber, not as a protocol to run yourself.
Where to start, and how long to wait
| Moving from | To | Start at | Gap |
|---|---|---|---|
| Wegovy | Zepbound | 2.5 mg — the very bottom | One week |
| Zepbound | Wegovy | 0.25 mg — the very bottom | One week |
| Ozempic | Mounjaro | 2.5 mg | One week |
| Saxenda (daily) | Wegovy (weekly) | 0.25 mg | A day — skip the next daily dose and start that week |
| Rybelsus (oral) | Injectable semaglutide | 0.25 mg. The oral and injected doses are not comparable in milligrams, so there is nothing to convert. | A day after the last tablet |
| Rybelsus | Ozempic tablets (its US replacement) | 4 mg from 7 mg, 9 mg from 14 mg. The label says the two are not substitutable milligram for milligram and rules out switching during the first 30 days | The day after the last Rybelsus tablet |
| Ozempic | Wegovy | Carry your dose across: same molecule, and the 0.25, 0.5 and 1 mg doses exist under both labels. Ozempic 2 mg has no Wegovy match, so ask which Wegovy dose to land on. | Replace the next weekly dose |
| Mounjaro | Zepbound | Carry your dose across — same molecule, same strengths | Replace the next weekly dose |
The last two rows are the exception. Those pairs are the same drug under a different label, so nothing about your body changes. Only the paperwork does, and that still means a fresh prescription and usually a fresh prior authorization.
Why you restart when it is the same class
After a year of doing fine, this is the instruction people are most tempted to skip.
Semaglutide and liraglutide act on the GLP-1 receptor. Tirzepatide acts on two: GLP-1 and GIP. Your gut may be thoroughly used to one of those and completely unacquainted with the other.
So someone sailing along on Wegovy at 2.4 mg with no nausea whatsoever can be floored by Zepbound at 7.5 mg, because nothing in their experience so far involved GIP. The ladder exists to introduce your digestive system to a molecule it has not met.
Why people switch
- The formulary moved. The most common reason by far, and nothing to do with your clinical situation.
- Not enough response at the top. Tirzepatide is a reasonable next move, and beat semaglutide when the two were compared directly.
- Side effects that will not settle. Sometimes it is worth going the other way: dropping from tirzepatide to semaglutide removes the GIP component altogether.
- You have run out of ladder. At the top of Saxenda, or at Wegovy's 7.2 mg maximum (for adults who have managed 2.4 mg comfortably for four weeks or longer), there is nowhere left to climb on that drug.
- Coming off a compounded product onto the brand. Start at the brand's lowest dose unless your prescriber has the exact compounded strength and history documented, and often nobody does.
What to watch during a switch
- Bad nausea in the first two weeks usually means the new starting dose was set too high. Drop to the bottom and climb slowly rather than pushing through.
- Hypoglycemia if you take insulin or a sulfonylurea. A switch deserves the same caution as a first start. Sort those doses out before the first new injection, not after.
- Never overlap two GLP-1s. If the new prescription lands before the old supply runs out, pick one. Do not bridge with both.
- A long prior-authorization delay can turn a switch into a restart. Wegovy's label drops you back to a lower dose once two weekly doses in a row have been missed, so do not resume at your old maintenance dose. Message your prescriber instead of deciding at home.
- Severe abdominal pain at any stage, especially reaching to the back. Stop and get seen the same day.
What this does not cover
Adults switching between GLP-1s for weight or type 2 diabetes. Not switching during pregnancy, where all of these should stop; not the surgery timing, which has its own page; not switching in children, where no standard exists; and not moving to a non-GLP-1 weight drug, which is a different decision altogether.
Where to go next
- Wegovy dose ladder, the schedule to follow when switching onto it.
- Zepbound ladder, the same for Zepbound.
- Wegovy against Zepbound sets out what the evidence says about which way to switch.
- Brand names against molecules explains why two of the rows above need no re-titration at all.